Close Menu

Biodesix

Biodesix this week reported results from the first prospective clinical trial of its proteomic lung cancer test Veristrat.

In March 2010, Austin, Texas-based diagnostics firm Vermillion launched sales of its OVA1 ovarian cancer test.

Bruker and the University of Victoria-Genome British Columbia Proteomics Centre said this week that they are collaborating on high-throughput iMALDI mass spec-based assays for determining genetic hemoglobin variants and diabetes risk.

Biodesix said this week it has entered a collaborative agreement with Bruker to support its VeriStrat diagnostic test, as well as future tests based on MALDI-TOF mass spectrometry.

NEW YORK (GenomeWeb News) – Biodesix said it has entered a collaborative agreement with Bruker Daltonics to support its VeriStrat diagnostic test as well as future tests based on MALDI-TOF mass spectrometry.

Researchers affiliated with Biodesix have completed a study indicating that the company's Veristrat test for identifying non-small cell lung cancer patients likely to respond to tyrosine kinase inhibitor treatment plays a significant role in guiding physician decisions.

Biodesix said this week that data from an analysis of serum and plasma samples from a Phase II non-small cell lung cancer study demonstrate that its Veristrat test is able to identify patients likely to benefit when treated with erlotinib – marketed by Roche as Tarceva – and erlo

NEW YORK (GenomeWeb News) – Biodesix today announced the closing of a $12 million extension of its Series D financing round.

People In The News

NEW YORK (GenomeWeb News) – Pacific Biosciences has appointed Jonas Korlach to chief scientific officer, a position previously held by Eric Schadt, who will remain a key scientific advisor to the company.

Quanterix announced this week it has appointed Paul Chapman as its new president and CEO, replacing Martin Madaus, who will continue at the company as executive chairman.

Pages

The US Patent and Trademark Office is opening another interference proceeding in the CRISPR patent fight.

There's increasing genetic evidence that a number of ancient hominins may have contributed to the human gene pool, according to Discover's The Crux blog.

The Japan News writes that Japan needs to seize the opportunity to ensure that a wide number of people benefit from personalized cancer treatments.

In Cell this week: messenger RNA expression and translation, RNA localization atlas, and more.